Developer docs
API playgroundTry for free, no card

Search company profiles

Nine Diagnostics

Full company profile

uuid0003vek

Namestring
Nine Diagnostics
Legal namestring
Nine Diagnostics
Company typeenum
Private
Founded yearint
2024
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology diagnostics, nanosensor cancer detection, molecular fingerprinting platform, liquid biopsy diagnostics, biomarker discovery technology
Industry5 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Precision Cancer Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Platform Licensing
TypeLicensing Royalties
Description

The company develops and commercializes its AI-enabled nanosensor diagnostic platform. Revenue is expected to come from licensing the technology to healthcare providers, pharmaceutical companies, and diagnostic laboratories. The platform supports both early detection and treatment monitoring applications.

ninediagnostics.xyz
2Biomarker and Diagnostic Services
TypeProfessional Services
Description

Providing diagnostic services using the nanosensor platform for cancer detection and treatment monitoring. The platform enables clinicians to access earlier markers for treatment effectiveness.

ninediagnostics.xyz
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Nine Diagnostics develops an AI-enabled nanosensor diagnostic platform that uses fluorescent carbon nanotube sensors to detect molecular fingerprints in small patient samples (e.g., blood serum). Machine learning algorithms decode these molecular fingerprints into clinically actionable insights for cancer detection, treatment selection, dosing optimization, and real-time treatment effectiveness monitoring. The platform integrates multidimensional health data including clinical, environmental, and social factors to create holistic patient profiles.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Every 4-week delay in cancer treatment causes up to 28% increase in mortality risk - Nine Diagnostics' faster feedback loops can reduce this delay
+1 more record
Product overview1 text field

Nine Diagnostics offers a unified AI-enabled nanosensor platform that combines fluorescent carbon nanotube sensing technology with machine learning algorithms. The core platform captures multidimensional molecular fingerprints from small-volume patient samples (such as blood serum) and processes them through machine perception systems to detect disease states and treatment effectiveness. The Molecular Fingerprinting Platform generates the sensor data, while the Machine Learning-Driven Diagnostic Platform translates these patterns into actionable clinical insights. The platform is designed for oncology applications including early cancer detection, treatment selection optimization, and disease monitoring.

Product and service1 record
1AI-Enabled Nanosensor Diagnostic Platform
CategoryPrecision Cancer Diagnostics
Description

A proprietary diagnostic platform combining fluorescent carbon nanotube nanosensors with machine learning pattern recognition to analyze biological samples (e.g., blood serum) at the molecular level, capturing real-time multidimensional health profiles for oncology applications including early cancer detection, treatment selection, dosing optimization, and treatment response monitoring. Targeted at oncologists, cancer researchers, pharmaceutical developers, and clinical research institutions.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1SCbio
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

Nine Diagnostics is participating in the Spring 2026 DRIVE Accelerator Biomarkers and Diagnostics track, run by SCbio in partnership with MassBio. The program brings together emerging companies developing next-generation diagnostic and biomarker technologies, with access to industry mentors and ecosystem partners including Eli Lilly, LabCorp, and other strategic partners focused on accelerating clinical translation.

massbio.org
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

Partnership through DRIVE Accelerator providing Nine Diagnostics with access to industry mentors, ecosystem partners, and potential commercialization pathways in the biomarkers and diagnostics space.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Co-founders Daniel Heller and Mijin Kim are part of the Weill Cornell Medicine team led by Lish Ndhlovu contributing to the ARPA-H LIGHT program. This program advances the ability to measure and interpret signals from the lymphatic system using AI-enabled nanosensor technologies, with potential applications in cancer progression, treatment response, and recurrence monitoring.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-16
Description

Nine Diagnostics and Orbits Oncology have executed a Letter of Intent to jointly develop a next-generation precision oncology diagnostics platform. The partnership combines Nine's nanosensor-based molecular fingerprinting platform with Orbit Oncology's organoid-based functional drug-response platform, enabling a closed-loop view of disease state and therapeutic efficacy. Initial focus on lung cancer and renal cell carcinoma with integrated workflow development and multimodal dataset generation.

5American Cancer Society BrightEdge
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-02-12
Description

Nine Diagnostics joined the American Cancer Society's BrightEdge Entrepreneurs Program, a highly selective initiative designed to accelerate promising oncology-focused startups. The program provides access to top-tier mentorship, investment opportunities, and strategic industry connections to support innovation in cancer treatment selection, dosing, optimization, and monitoring.

ninediagnostics.xyz
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-11-27
Description

U.S.-Dutch Consortium Collaboration in Women's Health supported by the Netherlands Innovation Network in Boston and Dutch Ministry of Economic Affairs. Building novel solutions for women's health through diagnostic tools and treatments development with leading Dutch and U.S. companies.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-11-14
Description

Nine Diagnostics was selected for Merck Digital Sciences Studio Cohort 3, receiving strategic guidance, direct investment, and connection opportunities within Merck. The 10-month accelerator program provides mentorship, workshops, office space, and up to $150,000 Azure Cloud computing credits. Collaboration with Merck to advance the AI-enabled nanosensor platform.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-09-19
Description

Nine Diagnostics was awarded the Novo Nordisk Golden Ticket for a residency at LabCentral, hosted by the Novo Nordisk Bio Innovation Hub. The award provides lab space, mentorship, and collaboration opportunities in LabCentral's vibrant and collaborative environment. LabCentral is a nonprofit launchpad supporting life sciences and biotech startups in Cambridge, MA.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Freenome is a multiomics blood-based early cancer detection platform using machine learning on cell-free DNA and other biomarkers. Directly comparable to Nine Diagnostics as both target biomarker-agnostic, ML-driven liquid biopsy diagnostics for early cancer detection.

2GRAIL
TypeDirect peer
Description

GRAIL's Galleri multi-cancer early detection test uses methylation-based cfDNA sequencing with ML. Highly comparable as a blood-based, AI-enabled early cancer screening platform targeting asymptomatic and high-risk populations.

TypeBroad incumbent
Description

Guardant Health provides liquid biopsy tests across screening, recurrence monitoring, and tumor profiling using cfDNA NGS. A well-established incumbent whose product portfolio overlaps Nine Diagnostics' oncology liquid biopsy and treatment monitoring use cases.

TypeBroad incumbent
Description

Exact Sciences (Cologuard, Oncotype DX) is a diagnostics incumbent expanding into liquid biopsy via Thrive Earlier Detection. Broadly comparable as a cancer screening and treatment selection diagnostics company leveraging novel molecular approaches.

TypeBroad incumbent
Description

Natera develops cell-free DNA tests including Signatera for MRD monitoring and Vantage for multi-cancer screening. An incumbent comparable on treatment monitoring and recurrence detection use cases that compete with Nine Diagnostics' platform.

TypeBroad incumbent
Description

Foundation Medicine (Roche) provides comprehensive genomic profiling and liquid biopsy services for oncology treatment selection. Comparable as a precision oncology diagnostics leader with broad pharma partnerships in companion diagnostics.

TypeEmerging player
Description

Adela is developing a blood-based multi-cancer screening platform using methylation enrichment and ML. An emerging peer sharing the biomarker-agnostic, ML-driven liquid biopsy thesis that targets broad cancer detection.

TypeEmerging player
Description

Predicine offers cfDNA/cfRNA-based liquid biopsy tests for tumor profiling and MRD with proprietary NGS assays. Comparable emerging player offering blood-based diagnostics for precision oncology similar to Nine Diagnostics' positioning.

TypeDirect peer
Description

Orbits Oncology is Nine Diagnostics' LOI partner developing an organoid-based functional drug-response platform. Highly comparable as a functional precision medicine company and immediate integration partner in the closed-loop diagnostics workflow.

10Thrive Earlier Detection
TypeDirect peer
Description

Thrive Earlier Detection (acquired by Exact Sciences) developed the CancerSEEK multi-analyte blood test combining cfDNA and protein biomarkers with ML. A direct comparator for early cancer detection via integrated multi-analyte liquid biopsy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nine Diagnostics

Precision Cancer Diagnosticsninediagnostics.xyz

Nine Diagnostics firmographics

Firmographics
Name
Nine Diagnostics
Legal name
Nine Diagnostics
Website
https://ninediagnostics.xyz
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Nine Diagnostics industry classification

Industry
Product category
Precision Cancer Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Precision oncology diagnostics
  • Nanosensor cancer detection
  • Molecular fingerprinting platform
  • Liquid biopsy diagnostics
  • Biomarker discovery technology

Where Nine Diagnostics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nine Diagnostics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Platform Licensing: The company develops and commercializes its AI-enabled nanosensor diagnostic platform. Revenue is expected to come from licensing the technology to healthcare providers, pharmaceutical companies, and diagnostic laboratories. The platform supports both early detection and treatment monitoring applications.
  2. Biomarker and Diagnostic Services: Providing diagnostic services using the nanosensor platform for cancer detection and treatment monitoring. The platform enables clinicians to access earlier markers for treatment effectiveness.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Nine Diagnostics product offering

Product offering

Core offering

Nine Diagnostics develops an AI-enabled nanosensor diagnostic platform that uses fluorescent carbon nanotube sensors to detect molecular fingerprints in small patient samples (e.g., blood serum). Machine learning algorithms decode these molecular fingerprints into clinically actionable insights for cancer detection, treatment selection, dosing optimization, and real-time treatment effectiveness monitoring. The platform integrates multidimensional health data including clinical, environmental, and social factors to create holistic patient profiles.

Product overview

Nine Diagnostics offers a unified AI-enabled nanosensor platform that combines fluorescent carbon nanotube sensing technology with machine learning algorithms. The core platform captures multidimensional molecular fingerprints from small-volume patient samples (such as blood serum) and processes them through machine perception systems to detect disease states and treatment effectiveness. The Molecular Fingerprinting Platform generates the sensor data, while the Machine Learning-Driven Diagnostic Platform translates these patterns into actionable clinical insights. The platform is designed for oncology applications including early cancer detection, treatment selection optimization, and disease monitoring.

Differentiator

Problem solved

Functional benefit

Products and services

  • AI-Enabled Nanosensor Diagnostic Platform A proprietary diagnostic platform combining fluorescent carbon nanotube nanosensors with machine learning pattern recognition to analyze biological samples (e.g., blood serum) at the molecular level, capturing real-time multidimensional health profiles for oncology applications including early cancer detection, treatment selection, dosing optimization, and treatment response monitoring. Targeted at oncologists, cancer researchers, pharmaceutical developers, and clinical research institutions.

Quantifiable outcome

  • Every 4-week delay in cancer treatment causes up to 28% increase in mortality risk - Nine Diagnostics' faster feedback loops can reduce this delay
  • +1 more outcomes

Companies that use Nine Diagnostics

Customer profile

Segments3 records

Ideal customer profiles3 records

Nine Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Nine Diagnostics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered major, core and minor.

  • SCbiomajorStrategic or Co-development Partner · 31 March 2026Nine Diagnostics is participating in the Spring 2026 DRIVE Accelerator Biomarkers and Diagnostics track, run by SCbio in partnership with MassBio. The program brings together emerging companies developing next-generation diagnostic and biomarker technologies, with access to industry mentors and ecosystem partners including Eli Lilly, LabCorp, and other strategic partners focused on accelerating clinical translation.
  • MassBiomajorStrategic or Co-development Partner · 31 March 2026Partnership through DRIVE Accelerator providing Nine Diagnostics with access to industry mentors, ecosystem partners, and potential commercialization pathways in the biomarkers and diagnostics space.
  • Weill Cornell MedicinecoreStrategic or Co-development Partner · 20 January 2026Co-founders Daniel Heller and Mijin Kim are part of the Weill Cornell Medicine team led by Lish Ndhlovu contributing to the ARPA-H LIGHT program. This program advances the ability to measure and interpret signals from the lymphatic system using AI-enabled nanosensor technologies, with potential applications in cancer progression, treatment response, and recurrence monitoring.
  • Orbits OncologycoreStrategic or Co-development Partner · 16 January 2026Nine Diagnostics and Orbits Oncology have executed a Letter of Intent to jointly develop a next-generation precision oncology diagnostics platform. The partnership combines Nine's nanosensor-based molecular fingerprinting platform with Orbit Oncology's organoid-based functional drug-response platform, enabling a closed-loop view of disease state and therapeutic efficacy. Initial focus on lung cancer and renal cell carcinoma with integrated workflow development and multimodal dataset generation.
  • American Cancer Society BrightEdgemajorStrategic or Co-development Partner · 12 February 2025Nine Diagnostics joined the American Cancer Society's BrightEdge Entrepreneurs Program, a highly selective initiative designed to accelerate promising oncology-focused startups. The program provides access to top-tier mentorship, investment opportunities, and strategic industry connections to support innovation in cancer treatment selection, dosing, optimization, and monitoring.
  • Netherlands Innovation NetworkminorGTM or Marketing Partner · 27 November 2024U.S.-Dutch Consortium Collaboration in Women's Health supported by the Netherlands Innovation Network in Boston and Dutch Ministry of Economic Affairs. Building novel solutions for women's health through diagnostic tools and treatments development with leading Dutch and U.S. companies.
  • Merck Digital Sciences StudiomajorStrategic or Co-development Partner · 14 November 2024Nine Diagnostics was selected for Merck Digital Sciences Studio Cohort 3, receiving strategic guidance, direct investment, and connection opportunities within Merck. The 10-month accelerator program provides mentorship, workshops, office space, and up to $150,000 Azure Cloud computing credits. Collaboration with Merck to advance the AI-enabled nanosensor platform.
  • LabCentralmajorStrategic or Co-development Partner · 19 September 2024Nine Diagnostics was awarded the Novo Nordisk Golden Ticket for a residency at LabCentral, hosted by the Novo Nordisk Bio Innovation Hub. The award provides lab space, mentorship, and collaboration opportunities in LabCentral's vibrant and collaborative environment. LabCentral is a nonprofit launchpad supporting life sciences and biotech startups in Cambridge, MA.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Nine Diagnostics competitors and assessment

Company assessment

Direct peers

  • Freenome: Freenome is a multiomics blood-based early cancer detection platform using machine learning on cell-free DNA and other biomarkers. Directly comparable to Nine Diagnostics as both target biomarker-agnostic, ML-driven liquid biopsy diagnostics for early cancer detection.
  • GRAIL: GRAIL's Galleri multi-cancer early detection test uses methylation-based cfDNA sequencing with ML. Highly comparable as a blood-based, AI-enabled early cancer screening platform targeting asymptomatic and high-risk populations.
  • Orbits Oncology: Orbits Oncology is Nine Diagnostics' LOI partner developing an organoid-based functional drug-response platform. Highly comparable as a functional precision medicine company and immediate integration partner in the closed-loop diagnostics workflow.
  • Thrive Earlier Detection: Thrive Earlier Detection (acquired by Exact Sciences) developed the CancerSEEK multi-analyte blood test combining cfDNA and protein biomarkers with ML. A direct comparator for early cancer detection via integrated multi-analyte liquid biopsy.

Broad incumbents

  • Guardant Health: Guardant Health provides liquid biopsy tests across screening, recurrence monitoring, and tumor profiling using cfDNA NGS. A well-established incumbent whose product portfolio overlaps Nine Diagnostics' oncology liquid biopsy and treatment monitoring use cases.
  • Exact Sciences: Exact Sciences (Cologuard, Oncotype DX) is a diagnostics incumbent expanding into liquid biopsy via Thrive Earlier Detection. Broadly comparable as a cancer screening and treatment selection diagnostics company leveraging novel molecular approaches.
  • Natera: Natera develops cell-free DNA tests including Signatera for MRD monitoring and Vantage for multi-cancer screening. An incumbent comparable on treatment monitoring and recurrence detection use cases that compete with Nine Diagnostics' platform.
  • Foundation Medicine: Foundation Medicine (Roche) provides comprehensive genomic profiling and liquid biopsy services for oncology treatment selection. Comparable as a precision oncology diagnostics leader with broad pharma partnerships in companion diagnostics.

Emerging players

  • Adela: Adela is developing a blood-based multi-cancer screening platform using methylation enrichment and ML. An emerging peer sharing the biomarker-agnostic, ML-driven liquid biopsy thesis that targets broad cancer detection.
  • Predicine: Predicine offers cfDNA/cfRNA-based liquid biopsy tests for tumor profiling and MRD with proprietary NGS assays. Comparable emerging player offering blood-based diagnostics for precision oncology similar to Nine Diagnostics' positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Nine Diagnostics social profiles

Digital presence

Nine Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nine Diagnostics leadership team

Management profile

Number of profiles

Profiles5 records

Nine Diagnostics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nine Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nine Diagnostics

What does Nine Diagnostics do?

Nine Diagnostics develops an AI-enabled nanosensor diagnostic platform that uses fluorescent carbon nanotube sensors to detect molecular fingerprints in small patient samples (e.g., blood serum). Machine learning algorithms decode these molecular fingerprints into clinically actionable insights for cancer detection, treatment selection, dosing optimization, and real-time treatment effectiveness monitoring. The platform integrates multidimensional health data including clinical, environmental, and social factors to create holistic patient profiles.

Is Nine Diagnostics a public or private company?

Nine Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nine Diagnostics founded?

Nine Diagnostics was founded in 2024. It employs 1 to 10 people.

Where is Nine Diagnostics based?

Nine Diagnostics is headquartered in Cambridge, United States, in the North America region.

How does Nine Diagnostics make money?

Two revenue lines are on record. Diagnostic Platform Licensing is the primary driver. The others are biomarker and Diagnostic Services.

Who are Nine Diagnostics's main competitors?

Direct peers on record are Freenome, GRAIL, Orbits Oncology and Thrive Earlier Detection. Broad incumbents are Guardant Health, Exact Sciences, Natera and Foundation Medicine. Emerging players are Adela and Predicine.

Does Nine Diagnostics have an API?

No public API is recorded for Nine Diagnostics.

What industry is Nine Diagnostics in?

Nine Diagnostics's product category is Precision Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SCbioNine Diagnostics: Biomarker and Diagnostic Startup Selected for Drive Accelerator ProgramNine Diagnostics, a biomarker and diagnostic startup, was selected for the Drive accelerator program. Its AI-enabled blood tests detect rapid treatment response from a simple blood draw, enabling faster clinical decisions and patient stratification. The platform is designed for oncology, immunology, and cell and gene therapy workflows.SCbioSCbio and MassBio Announce Eleven Startups Selected for Spring 2026 Drive CohortsSCbio and MassBio announced 11 startups selected for Spring 2026 Drive cohorts, with SCbio leading a biomarkers and diagnostics cohort and MassBio leading a biotech cohort. The cohorts will include curriculum modules and a sponsored lab bench, and Drive has supported 59 companies since 2022.NinediagnosticsNine Diagnostics Joins DRIVE Accelerator with SCbio and MassBioNine Diagnostics was selected for the Spring 2026 cohort of the Drive Accelerator, a program run by SCbio and MassBio. The program has supported 59 companies that raised $175 million and created nearly 100 jobs. Nine Diagnostics will join the Biomarkers and Diagnostics track, which includes curriculum partners Eli Lilly and LabCorp.NinediagnosticsNine Diagnostics Pitches at BioTools Innovator East Coast Road TourNine Diagnostics pitched its AI-enabled multi-omic nanosensor platform at the BioTools Innovator East Coast Pitch Event. The platform uses machine learning to generate molecular fingerprints from proteomic, metabolomic, and lipidomic data without predefined biomarkers. The company aims to validate the platform through research partnerships and build a commercialization pathway toward laboratory-developed tests.NinediagnosticsIndustrial Adoption of Carbon NanotubesA perspective in Nano Letters surveys 30 years of carbon nanotube research and documents industrial adoption across energy storage, electronics, and composites. It identifies a knowledge gap and argues against a blanket EU ban, noting an unmet need to differentiate nanotube types. The paper forms the scientific foundation of Nine Diagnostics, which uses semiconducting single-walled carbon nanotubes for its cancer diagnostic platform.NjiiMDSS Startups Making Waves: From ARPA-H Awards to AI-Driven Cancer BreakthroughsThe Merck Digital Sciences Studio (MDSS) has achieved significant milestones with its portfolio companies, particularly through the announcement of a $23.6 million ARPA-H award to Serinus Bio for cancer predictive modeling. Additionally, Nine Diagnostics and Orbits Oncology have partnered to enhance biomarker discovery in oncology using their AI-driven technologies. These developments underscore the impact of MDSS in fostering innovation in precision oncology.